Various cells secrete exosomes, such as B lymphocyte cell lines, mast cells, dendritic cells, endothelial cells, stem cells, neuronal cells, endothelial cells, and cancer cells (
1). Exosomes are released by diseased or viable cell types in a continuous way or by activation into interstitial spaces or body fluid. It is notable that these exosomes are released by cells in vitro (
2). As shown by studies, exosomes can be used to develop cell-free vaccines for a variety of diseases (
3). Studies have also mentioned their role in normal physiological conditions (such as immune response, lactation, and neuronal function) and pathophysiological conditions (such as the progression and development of liver diseases, cancer, and neurodegenerative diseases) (
4). Given the cell origin, exosomes control morphogen transporters in creating polarity in differentiation and development (
5). A significant necessity in tissue engineering is inducing lineage-specific differentiation of stem cells reliably and predictably. Generally, biomaterial selection and properties depend on this factor. Growth factor delivery systems are usually used to induce lineage-specific differentiation of stem cells. Using growth factors such as bone morphogenetic factor 2 (BMP2) for clinical applications has been used by the US Food and Drug Administration (FDA). Still, available clinical uses of growth factors have notable ectopic interactions and side effects. Several problems have been reported caused by BMP2, which are major concerns for clinicians (
6). To develop biomimetic approaches and solve the issue of using growth factors and complicated controlled release mechanisms, the chance of using exosomes specific to cell type has been studied (
7). In general, it is believed that exosomes act as a mediator of cellular homeostasis through secreting cellular waste (
8).
Research projects on exosomes have been chiefly on cancer biology and immunology (
9). Still, following the findings regarding their role in messenger RNA (mRNA) and microRNA (miRNA) transference (
10), many researchers have worked on using them in regenerative medicine. Studies have shown that exosomes enhance the proliferative capacity of epithelial and mesenchymal cells through the mitogen-activated protein kinase (MAPK) pathway (
11). Exosomes extracted from endothelial progenitor cells, endothelial cells, and mesenchymal stem cells demonstrate proangiogenic characteristics explained by the presence of miRNAs localized in them (
12). Eventually, exosomes are recognized as the driving force of immunomodulatory effects of mesenchymal stem cells (MSCs) by triggering the secretion of anti-inflammatory cytokines and accelerating the formation of M2 macrophages (
13). Despite the findings supporting exosomes’ capabilities to be used in regenerative medicine, their capacity to cause lineage-specific differentiation of stem cells is not supported by reliable evidence. Moreover, the role of using exosomes secreted from one partition in the general biology of the recipient cell requires further studies. Our hypothesis states that exosomes from differential cells can cause lineage-specific differentiation of native MSCs.